A US based biotechnology company approached BAP Pharma to enquire about providing life-saving early access to a promising two drug treatment that was undergoing phase II trials.
Urgent Named Patient Supply
An urgent request was received by BAP Pharma in December of 2020 from a multinational healthcare company, for assistance in gaining access to an unlicensed medicine for a 4-month-old critical patient in India.
Eliminating Delays to Clinical Studies
BAP Pharma received an urgent request from a new client in October 2021, for an order of medical devices. These needed to be sourced from a specific supplier for use in an ongoing clinical study.
Circumventing manufacturing issues due to Covid-19
BAP was able to source the full quantity of vaccines, with full documentation, in just 2 weeks, ensuring continuity of supply for the client’s trial.
Policy Change Management with Manufacturer
BAP differentiated itself from its competitors by being the only company able to influence the manufacturer to change its policy.
Meeting tight deadlines for a client
BAP Pharma provided great flexibility and used our new BAP GmbH site to leverage deals that would otherwise not be available.
Supplying difficult to access documentation
BAP’s results focused approach ensured the product reached patients, and without potentially costly delays to the clinical trial.
Please complete the form below to access your copy of this .
